Abstract:A subgroup of patients with schizophrenia is believed to have aberrant excess of glutamate in the frontal cortex; this subgroup is thought to show poor response to first-line antipsychotic treatments that focus on dopamine blockade. If we can identify this subgroup early in the course of illness, we can reduce the repeated use of first-line antipsychotics and potentially stratify first-episode patients to intervene early with second-line treatments such as clozapine. The use of proton magnetic resonance spectroscopy (1H-MRS) to measure glutamate and Glx (glutamate plus glutamine) may provide a means for such a stratification. We must first establish if there is robust evidence linking elevations in anterior cingulate cortex (ACC) glutamate metabolites to poor response, and determine if the use of antipsychotics worsens the glutamatergic excess in eventual nonresponders. In this study, we estimated glutamate levels at baseline in 42 drug-naive patients with schizophrenia. We then treated them all with risperidone at a standard dose range of 2-6 mg/day and followed them up for 3 months to categorize their response status. We expected to see baseline “hyperglutamatergia” in nonresponders, and expected this to worsen over time at the follow-up. In line with our predictions, nonresponders had higher glutamate than responders, but patients as a group did not differ in glutamate and Glx from the healthy control (HC) group before treatment-onset (F 1,79 = 3.20, p = 0.046, partial η2 = 0.075). Glutamatergic metabolites did not change significantly over time in both nonresponders and responders over the 3 months of antipsychotic exposure (F 1,31 = 1.26, p = 0.270, partial η2 = 0.039). We conclude that the use of antipsychotics without prior knowledge of later response delays symptom relief in a subgroup of first-episode patients, but does not worsen the glutamatergic excess seen at the baseline. Given the current practice of nonstratified use of antipsychotics, longer-time follow-up MRS studies are required to see if improvement in symptoms accompanies a dynamic shift in glutamate profile.

The Predictive Value of Baseline NAA/Cr for Treatment Response of First-Episode Schizophrenia: A 1H MRS Study

A proton magnetic resonance spectroscopy imaging study on prefrontal lobe and hippocampus in patients with adolescence-onset schizophrenia

Correlation of neurochemical metabolism with memory function in young adult patients with first-episode depression studied with proton magnetic resonance spectroscopy]

A 1H Magnetic Resonance Spectroscopy Imaging Study on Prefrontal and Hippocampus in Patients with Depression

Longitudinal follow-up of asymmetric changes by proton magnetic resonance spectroscopy in first-episode schizophrenia patients

Detection of Metabolites in the White Matter of Frontal Lobes and Hippocampus with Proton in First‐episode Treatment‐naïve Schizophrenia Patients

Analysis of ~1H-MRS in patients with depression after basal ganglia infarction

Analysis of ¹H-MRS in patients with depression after basal ganglia infarction]

The relationship between the alterations in metabolite levels in the dorsolateral prefrontal cortex and clinical symptoms of patients with first-episode schizophrenia: a one year follow-up study.

N-acetylaspartate reduction in the medial prefrontal cortex following 8 weeks of risperidone treatment in first-episode drug-naïve schizophrenia patients.

Metabolite differences in the medial prefrontal cortex in schizophrenia patients with and without persistent auditory verbal hallucinations: a 1 H MRS study

Metabolite differences in the medial prefrontal cortex in schizophrenia patients with and without persistent auditory verbal hallucinations: a <SUP>1</SUP>H MRS study

A proton magnetic resonance spectroscopy imaging study on prefrontal lobe and hippocampus in male patients with first-episode mania

A Proton Magnetic Resonance Spectroscopy Imaging Study on Prefrontal Lobe and Hippocampus in Patients with First-Episode Positive Symptoms of Schizophrenia

Comparative Study of Proton Magnetic Resonance Spectroscopy on Frontal Lobe Between Patients with Paranoid Schizophrenia and Patients with Bipolar Mania

Enhanced Baseline Activity in the Left Ventromedial Putamen Predicts Individual Treatment Response in Drug-Naive, First-Episode Schizophrenia: Results from Two Independent Study Samples.

A Proton Magnetic Resonance Spectroscopy Research on Hippocampus in Patients with Treatment-Resistant Depression

A 1H Magnetic Resonance Spectroscopy study on Hippocampns of Patients with First-episode Major Depressive Disorder

Prediction of Early Response to Overall Treatment for Schizophrenia: A Functional Magnetic Resonance Imaging Study.

Reduced Brain Activity in the Right Putamen As an Early Predictor for Treatment Response in Drug-Naive, First-Episode Schizophrenia

Glutamatergic Basis of Antipsychotic Response in First-Episode Psychosis: a Dual Voxel Study of the Anterior Cingulate Cortex